Portman Square Capital’s Merck MRK Stock Holding History

Portman Square Capital’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-8,418	Closed	-$934K	–	357
2022 Q4	$934K	Buy	+8,418	New	+$860K	0.07%	202

Other funds holding MRK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Portman Square Capital's MRK Position: Q1 2023 in Review

Portman Square Capital sold out of Merck (MRK) in Q1 2023, closing a stake of 8,418 shares — an estimated $934K sold.

Portman Square Capital first reported a position in MRK in Q4 2022 and held it in 1 quarter. The position peaked at $934K in Q4 2022. 3,180 funds tracked by Wall St. Rank hold MRK as of Q1 2023.

Portman Square Capital reported no remaining Merck position as of Q1 2023 after selling out during the quarter.
Portman Square Capital sold 8,418 Merck shares in Q1 2023, an estimated $934K.
Portman Square Capital first reported a position in Merck in Q4 2022 and held it in 1 quarter.
Portman Square Capital's Merck position peaked at $934K in Q4 2022.
3,180 funds tracked by Wall St. Rank held Merck as of Q1 2023.

Based on Portman Square Capital's 13F filing for Q1 2023, filed 4 May 2023.